Subjects -> MEDICAL SCIENCES (Total: 8186 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 153 of 153 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 3)
Acta Haematologica     Full-text available via subscription   (Followers: 18)
Acta Haematologica Polonica     Open Access  
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 46)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 14)
Archives of Hematology Case Reports and Reviews     Open Access  
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 25)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 3)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 285)
Blood Advances     Open Access   (Followers: 9)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 21)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 5)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 27)
Blood Pressure     Open Access   (Followers: 1)
Blood Pressure Monitoring     Hybrid Journal   (Followers: 2)
Blood Purification     Full-text available via subscription   (Followers: 5)
Blood Reviews     Hybrid Journal   (Followers: 20)
BMC Hematology     Open Access   (Followers: 6)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 23)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 15)
British Journal of Diabetes & Vascular Disease     Open Access   (Followers: 14)
British Journal of Haematology     Hybrid Journal   (Followers: 54)
British Journal of Primary Care Nursing - Cardiovascular Disease, Diabetes and Kidney Care     Full-text available via subscription   (Followers: 7)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 9)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 28)
Clinical Diabetes     Full-text available via subscription   (Followers: 30)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 14)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Clinical Lymphoma Myeloma and Leukemia     Hybrid Journal   (Followers: 6)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 1)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 14)
Current Diabetes Reviews     Hybrid Journal   (Followers: 13)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 14)
Cytotherapy     Full-text available via subscription   (Followers: 1)
Der Diabetologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 251)
Diabetes aktuell     Hybrid Journal   (Followers: 2)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 8)
Diabetes Care     Full-text available via subscription   (Followers: 281)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 10)
Diabetes Management     Full-text available via subscription   (Followers: 7)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 18)
Diabetes Spectrum     Full-text available via subscription   (Followers: 14)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 8)
Diabetes Therapy     Open Access   (Followers: 13)
Diabetic Foot & Ankle     Open Access   (Followers: 10)
Diabetic Medicine     Hybrid Journal   (Followers: 92)
Diabetologia     Hybrid Journal   (Followers: 105)
Diabetologia Kliniczna     Hybrid Journal  
Diabetologie und Stoffwechsel     Hybrid Journal  
Egyptian Journal of Haematology     Open Access  
Egyptian Journal of Hematology and Bone Marrow Transplantation     Open Access   (Followers: 10)
eJHaem     Open Access   (Followers: 1)
European Journal of Haematology     Hybrid Journal   (Followers: 12)
Experimental Hematology     Hybrid Journal   (Followers: 3)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Global Journal of Transfusion Medicine     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 35)
Haemophilia     Hybrid Journal   (Followers: 15)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematología     Open Access  
Hematology     Open Access   (Followers: 9)
Hematology Reports     Open Access   (Followers: 4)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hematology/Oncology and Stem Cell Therapy     Open Access   (Followers: 5)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 3)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access   (Followers: 1)
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 5)
International Journal of Diabetes Research     Open Access   (Followers: 6)
International Journal of Hematologic Oncology     Open Access   (Followers: 2)
International Journal of Hematology     Hybrid Journal   (Followers: 3)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Hematology-Oncology and Stem Cell Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 24)
Iraqi Journal of Hematology     Open Access  
JMIR Diabetes     Open Access  
Journal of Blood Disorders & Transfusion     Open Access   (Followers: 3)
Journal of Cell Science & Therapy     Open Access   (Followers: 1)
Journal of Applied Hematology     Open Access   (Followers: 2)
Journal of Blood Medicine     Open Access  
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 12)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 13)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 6)
Journal of Diabetes Investigation     Open Access   (Followers: 6)
Journal of Diabetes Mellitus     Open Access   (Followers: 4)
Journal of Diabetes Research     Open Access   (Followers: 9)
Journal of Diabetes Research     Open Access   (Followers: 4)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology     Open Access   (Followers: 2)
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Hypo & Hyperglycemia     Partially Free   (Followers: 1)
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 6)
Journal of Social Health and Diabetes     Open Access  
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 52)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 30)
Journal of Transfusion Medicine     Full-text available via subscription  
Kidney and Blood Pressure Research     Open Access   (Followers: 3)
Leukemia     Hybrid Journal   (Followers: 23)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 13)
Leukemia Research     Hybrid Journal   (Followers: 9)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Mediterranean Journal of Hematology and Infectious Diseases     Open Access  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 18)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 6)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Plasmatology     Open Access   (Followers: 1)
Platelets     Hybrid Journal   (Followers: 2)
Practical Diabetes     Hybrid Journal   (Followers: 4)
Primary Care Diabetes     Hybrid Journal   (Followers: 16)
Research & Reviews : Journal of Oncology and Hematology     Full-text available via subscription  
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 2)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 28)
Thalassemia Reports     Open Access   (Followers: 1)
The Lancet Haematology     Full-text available via subscription   (Followers: 42)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 110)
Thrombosis Research     Hybrid Journal   (Followers: 30)
Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie     Hybrid Journal  
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 11)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Journal Cover
Thrombosis & Haemostasis
Number of Followers: 110  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0340-6245 - ISSN (Online) 2567-689X
Published by Thieme Publishing Group Homepage  [233 journals]
  • Glycosaminoglycans: Participants in Microvascular Coagulation of Sepsis

    • Free pre-print version: Loading...

      Authors: Li; Nanxi, Hao, Ruolin, Ren, Peng, Wang, Jingya, Dong, Jiahui, Ye, Tong, Zhao, Danyang, Qiao, Xuan, Meng, Zhiyun, Gan, Hui, Liu, Shuchen, Sun, Yunbo, Dou, Guifang, Gu, Ruolan
      Abstract: Sepsis represents a syndromic response to infection and frequently acts as a common pathway leading to fatality in the context of various infectious diseases globally. The pathology of severe sepsis is marked by an excess of inflammation and activated coagulation. A substantial contributor to mortality in sepsis patients is widespread microvascular thrombosis-induced organ dysfunction. Multiple lines of evidence support the notion that sepsis induces endothelial damage, leading to the release of glycosaminoglycans, potentially causing microvascular dysfunction. This review aims to initially elucidate the relationship among endothelial damage, excessive inflammation, and thrombosis in sepsis. Following this, we present a summary of the involvement of glycosaminoglycans in coagulation, elucidating interactions among glycosaminoglycans, platelets, and inflammatory cells. In this section, we also introduce a reasoned generalization of potential signal pathways wherein glycosaminoglycans play a role in clotting. Finally, we discuss current methods for detecting microvascular conditions in sepsis patients from the perspective of glycosaminoglycans. In conclusion, it is imperative to pay closer attention to the role of glycosaminoglycans in the mechanism of microvascular thrombosis in sepsis. Dynamically assessing glycosaminoglycan levels in patients may aid in predicting microvascular conditions, enabling the monitoring of disease progression, adjustment of clinical treatment schemes, and mitigation of both acute and long-term adverse outcomes associated with sepsis.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-02-15T08:43:53+0100
      DOI: 10.1055/a-2250-3166
       
  • Icaritin Sensitizes Thrombin- and TxA2-Induced Platelet Activation and
           Promotes Hemostasis via Enhancing PLCγ2-PKC Signaling Pathways

    • Free pre-print version: Loading...

      Authors: Zhu; Zhixiang, Luo, Yanggan, Liao, Hanjing, Guo, Ran, Hao, Doudou, Lu, Zihan, Huang, Manjing, Sun, Chenghong, Yao, Jingchun, Wei, Ning, Zeng, Kewu, Tu, Pengfei, Zhang, Guimin
      Abstract: Background Vascular injury results in uncontrollable hemorrhage in hemorrhagic diseases and excessive antithrombotic therapy. Safe and efficient hemostatic agents which can be orally administered are urgently needed. Platelets play indispensable roles in hemostasis, but there is no drug exerting hemostatic effects through enhancing platelet function. Methods The regulatory effects of icaritin, a natural compound isolated from Herba Epimedii, on the dense granule release, thromboxane A2 (TxA2) synthesis, α-granule release, activation of integrin αIIbβ3, and aggregation of platelets induced by multiple agonists were investigated. The effects of icaritin on tail vein bleeding times of warfarin-treated mice were also evaluated. Furthermore, we investigated the underlying mechanisms by which icaritin exerted its pharmacological effects. Results Icaritin alone did not activate platelets, but significantly potentiated the dense granule release, α-granule release, activation of integrin αIIbβ3, and aggregation of platelets induced by thrombin and U46619. Icaritin also shortened tail vein bleeding times of mice treated with warfarin. In addition, phosphorylated proteome analysis, immunoblotting analysis, and pharmacological research revealed that icaritin sensitized the activation of phospholipase Cγ2 (PLCγ2)-protein kinase C (PKC) signaling pathways, which play important roles in platelet activation. Conclusion Icaritin can sensitize platelet activation induced by thrombin and TxA2 through enhancing the activation of PLCγ2-PKC signaling pathways and promote hemostasis, and has potential to be developed into a novel orally deliverable therapeutic agent for hemorrhages.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-02-09T09:09:27+0100
      DOI: 10.1055/a-2245-8457
       
  • Anticoagulation in Patients with Isolated Distal Deep Vein Thrombosis:
           Bringing the Puzzle Together

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/a-2250-3298



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2024-02-07T12:59:42+0100
       
  • Proteomic Characterization of Plasma in Lemierre's Syndrome

    • Free pre-print version: Loading...

      Authors: Nygren; David, Torisson, Gustav, Happonen, Lotta, Mellhammar, Lisa, Linder, Adam, Elf, Johan, Yan, Hong, Welinder, Charlotte, Holm, Karin
      Abstract: Background The underlying mechanisms of thrombosis in Lemierre's syndrome and other septic thrombophlebitis are incompletely understood. Therefore, in this case control study we aimed to generate hypotheses on its pathogenesis by studying the plasma proteome in patients with these conditions. Methods All patients with Lemierre's syndrome in the Skåne Region, Sweden, were enrolled prospectively during 2017 to 2021 as cases. Age-matched patients with other severe infections were enrolled as controls. Patient plasma samples were analyzed using label-free data-independent acquisition liquid chromatography tandem mass spectrometry. Differentially expressed proteins in Lemierre's syndrome versus other severe infections were highlighted. Functions of differentially expressed proteins were defined based on a literature search focused on previous associations with thrombosis. Results Eight patients with Lemierre's syndrome and 15 with other severe infections were compared. Here, 20/449 identified proteins were differentially expressed between the groups. Of these, 14/20 had functions previously associated with thrombosis. Twelve of 14 had a suggested prothrombotic effect in Lemierre's syndrome, whereas 2/14 had a suggested antithrombotic effect. Conclusion Proteins involved in several thrombogenic pathways were differentially expressed in Lemierre's syndrome compared to other severe infections. Among identified proteins, several were associated with endothelial damage, platelet activation, and degranulation, and warrant further targeted studies.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-02-07T12:48:52+0100
      DOI: 10.1055/a-2195-3927
       
  • DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor
           in Polycythemia Vera Patients: An Observational Study

    • Free pre-print version: Loading...

      Authors: Segura-Díaz; Adrián, Stuckey, Ruth, Florido, Yanira, Sobas, Marta, Álvarez-Larrán, Alberto, Ferrer-Marín, Francisca, Pérez-Encinas, Manuel, Carreño-Tarragona, Gonzalo, Fox, María L., Tazón Vega, Barbara, Cuevas, Beatriz, López Rodríguez, Juan F., Farías-Sánchez, Nuria, González-Martín, Jesús M., Gómez-Casares, María T., Bilbao-Sieyro, Cristina
      Abstract: Background Polycythemia vera (PV) patients are classified as high or low thrombotic risk based on age and prior history of thrombosis. Despite adherence to treatment recommendations, vascular events remain frequent, leading us to question whether thrombotic risk stratification could be improved. We previously reported an association between thrombotic events and mutations in DTA genes (DNMT3A, TET2, and ASXL1). The objective of this study was to confirm this observation in a larger series of PV patients. Methods PV patients with a minimum follow-up of 3 years were recruited from 8 European centers. Medical history was searched for thrombotic event recorded at any time and next-generation sequencing carried out with a myeloid panel. Multivariable logistic regression evaluated the impact of variables on thrombotic risk. Kaplan–Meier thrombosis-free survival curves were compared by the log rank test. Associations in the total cohort were confirmed in a case–control study to exclude selection bias. Results Of the 136 patients recruited, 74 (56.1%) had a thrombotic event, with an incidence density of 2.83/100 person-years. In multivariable analysis, DTA mutation was a risk factor for thrombotic event, being predictive for shorter thrombosis-free survival in the whole cohort (p = 0.007), as well as in low-risk patients (p = 0.039) and older patients (p = 0.009), but not for patients with a prediagnostic event. A gender- and age-matched case–control study confirmed the increased risk of thrombotic event for PV patients with a DTA mutation. Conclusion Our results support the use of molecular testing at diagnosis to help predict which PV patients are at higher risk of developing thrombosis.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-30T10:43:46+0100
      DOI: 10.1055/a-2239-9265
       
  • Risk of Depression after Venous Thromboembolism in Patients with
           Hematological Cancer: A Population-Based Cohort Study

    • Free pre-print version: Loading...

      Authors: Steiner; Daniel, Horváth-Puhó, Erzsébet, Jørgensen, Helle, Laugesen, Kristina, Ay, Cihan, Sørensen, Henrik Toft
      Abstract: Background Venous thromboembolism (VTE) may complicate the clinical course of cancer patients and add to their psychological burden. Objectives We aimed to investigate the association between VTE and risk of subsequent depression in patients with hematological cancer. Patients and Methods We conducted a population-based cohort study using Danish national health registries. Between 1995 and 2020, we identified 1,190 patients with hematological cancer and incident VTE diagnosed within 6 months before to 1 year after cancer diagnosis. A comparison cohort of patients with hematological cancer without VTE (n = 5,325) was matched by sex, year of birth, cancer type, and year of cancer diagnosis. Patients were followed until diagnosis of depression, emigration, death, study end (2021), or for a maximum of 3 years. Depression was defined as hospital discharge diagnosis of depression or ≥1 prescription for antidepressants. Absolute risks of depression were computed with cumulative incidence functions, treating death as competing event. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed using Cox proportional hazards regression models, adjusting for comorbidities. Results Depression was observed in 158 hematological cancer patients with and 585 without VTE. The 3-year absolute risks of depression were 13.3% (95% CI: 11.5–15.3%) in the VTE cancer cohort and 11.1% (95% CI: 10.3–12.0%) in the comparison cancer cohort, corresponding to a risk difference of 2.2% (95% CI: -1.8–6.5%). VTE was associated with an increased relative risk of depression (adjusted HR: 1.56, 95% CI: 1.28–1.90). Conclusion VTE was associated with an elevated risk of subsequent depression in patients with hematological cancer.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-18T11:03:37+0100
      DOI: 10.1055/a-2225-5428
       
  • Platelet-Derived TGF-β1 Promotes Deep Vein Thrombosis

    • Free pre-print version: Loading...

      Authors: Zhang; Sixuan, Li, Yingying, Zhang, Jie, Sun, Yueyue, Chu, Xiang, Gui, Xiang, Tong, Huan, Ding, Yangyang, Ju, Wen, Xu, Mengdi, Li, Zhenyu, Zeng, Lingyu, Xu, Kailin, Qiao, Jianlin
      Abstract: Background Transforming growth factor-β1 (TGF-β1) modulates multiple cellular functions during development and tissue homeostasis. A large amount of TGF-β1 is stored in platelet α-granules and released upon platelet activation. Whether platelet-derived TGF-β1 plays a role in venous thrombosis remains unclear. This study intends to assess the role of platelet-derived TGF-β1 in the development of venous thrombosis in mice. Material and Methods TGF-β1flox/flox and platelet-specific TGF-β1−/− mice were utilized to assess platelet function in vitro, arterial thrombosis induced by FeCl3, tail bleeding time, prothrombin time (PT), activated partial thromboplastin time (APTT), and deep vein thrombosis induced through ligation of the inferior vena cava (IVC). The IVC sample was collected to measure accumulation of neutrophils, monocytes, and the formation of neutrophil extracellular traps (NETs) by immunofluorescence staining. Results TGF-β1 deficiency in platelets did not affect the number of circulating platelets, platelet aggregation, adenosine triphosphate release, and integrin αIIbβ3 activation. Meanwhile, TGF-β1 deficiency did not alter the arterial thrombus formation, hemostasis, and coagulation time (PT and APTT), but significantly impaired venous thrombus formation, inhibited the recruitment and accumulation of neutrophils and monocytes in thrombi, as well as reduced formation of NETs and platelet-neutrophil complex. In addition, adoptive transfer of TGF-β1flox/flox platelets to TGF-β1−/− mice rescued the impaired venous thrombus formation, recruitment of leukocytes and monocytes, as well as the NETs formation. Conclusion In conclusion, platelet-derived TGF-β1 positively modulates venous thrombus formation in mice, indicating that targeting TGF-β1 might be a novel approach for treating venous thrombosis without increasing the risk of bleeding.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-15T07:38:44+0100
      DOI: 10.1055/a-2235-7485
       
  • Percutaneous Coronary Intervention in Acute Coronary Syndrome with
           Mild-to-Moderate Thrombocytopenia

    • Free pre-print version: Loading...

      Authors: Ye; Yicong, Hao, Yongchen, Zhao, Xiliang, Liu, Jun, Yang, Na, Smith, Sidney C., Huo, Yong, Fonarow, Gregg C., Ge, Junbo, Morgan, Louise, Sun, Zhaoqing, Hu, Danqing, Yang, Yiqian, Ma, Chang-Sheng, Zhao, Dong, Han, Yaling, Liu, Jing, Zeng, Yong
      Abstract: Background Baseline thrombocytopenia is commonly observed in patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI). Aim The purpose of this analysis was to investigate safety and effectiveness of PCI in ACS patients with baseline mild-to-moderate thrombocytopenia. Methods The data were collected from the Improving Care for Cardiovascular Disease in China–Acute Coronary Syndrome project. A total of 50,009 ACS patients were recruited between July 2017 and December 2019. Among them, there were 6,413 patients with mild-to-moderate thrombocytopenia, defined as a platelet count of ≥50 × 109/L and
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-10T12:33:44+0100
      DOI: 10.1055/a-2225-5263
       
  • The Effect of Cytokine Adsorption on Leukocyte and Platelet Activation
           after Extracorporeal Cardiopulmonary Resuscitation

    • Free pre-print version: Loading...

      Authors: Zahn; Timm, Schanze, Nancy, Staudacher, Dawid L., Wengenmayer, Tobias, Maier, Sven, Benk, Christoph, Gauchel, Nadine, Duerschmied, Daniel, Supady, Alexander
      Abstract: Background Post-cardiac arrest syndrome (PCAS) is a frequent complication following successful cardiopulmonary resuscitation and correlates with poor outcome. PCAS is characterized by an excessive inflammatory response to whole-body ischemia and reperfusion. Cytokine adsorption was suggested as an adjunctive treatment option for the removal of cytokines from the patients' blood to restore the physiological equilibrium of pro- and anti-inflammatory activity and thus mitigate hemodynamic instability and end-organ complications. Material and Methods To better understand the cellular effects of cytokine adsorption in patients receiving extracorporeal cardiopulmonary resuscitation (ECPR) after in- and out-of-hospital cardiac arrest, we compared the activation status of neutrophils, monocytes, and platelets as well as the formation of platelet–leukocyte complexes in intravenous whole blood samples from an exploratory subgroup (n = 24) from the randomized CYTER study. Result At 48 hours after initiation of ECPR, flow cytometry analyses did neither reveal significant differences in neutrophil (CD11b, CD66b, L-selectin, and PSGL-1) and monocyte (CD11b, L-selectin, and PSGL-1) surface molecule expression nor in circulating platelet–monocyte complexes between patients receiving cytokine adsorption and those without. Conclusion Data did not show a relevant effect of cytokine adsorption on neutrophil and monocyte activation during the first 48 hours after initiation of ECPR.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-10T12:28:57+0100
      DOI: 10.1055/a-2225-5173
       
  • Iron Macrophages: Dance of Death and MMP Release in Intraplaque Hemorrhage

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/s-0043-1778071



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2024-01-09T11:51:07+0100
       
  • Identification of Factor XIII β-Sandwich Residues Mediating Glutamine
           Substrate Binding and Activation Peptide Cleavage

    • Free pre-print version: Loading...

      Authors: Mohammed; Rameesa D. Syed, Piell, Kellianne M., Maurer, Muriel C.
      Abstract: Background Factor XIII (FXIII) forms covalent crosslinks across plasma and cellular substrates and has roles in hemostasis, wound healing, and bone metabolism. FXIII activity is implicated in venous thromboembolism (VTE) and is a target for developing pharmaceuticals, which requires understanding FXIII – substrate interactions. Previous studies proposed the β-sandwich domain of the FXIII A subunit (FXIII-A) exhibits substrate recognition sites. Material and Methods Recombinant FXIII-A proteins (WT, K156E, F157L, R158Q/E, R171Q, and R174E) were generated to identify FXIII-A residues mediating substrate recognition. Proteolytic (FXIII-A*) and non-proteolytic (FXIII-A°) forms were analyzed for activation and crosslinking activities toward physiological substrates using SDS-PAGE and MALDI-TOF MS. Results All FXIII-A* variants displayed reduced crosslinking abilities compared to WT for Fbg αC (233 – 425), fibrin, and actin. FXIII-A* WT activity was greater than A°, suggesting the binding site is more exposed in FXIII-A*. With Fbg αC (233 – 425), FXIII-A* variants R158Q/E, R171Q, and R174E exhibited decreased activities approaching those of FXIII-A°. However, with a peptide substrate, FXIII-A* WT and variants showed similar crosslinking suggesting the recognition site is distant from the catalytic site. Surprisingly, FXIII-A R158E and R171Q displayed slower thrombin activation than WT, potentially due to loss of crucial H-bonding with neighboring activation peptide (AP) residues. Conclusion In conclusion, FXIII-A residues K156, F157, R158, R171, and R174 are part of a binding site for physiological substrates [fibrin (α and γ) and actin]. Moreover, R158 and R171 control AP cleavage during thrombin activation. These investigations provide new molecular details on FXIII – substrate interactions that control crosslinking abilities.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-09T11:47:20+0100
      DOI: 10.1055/a-2220-7544
       
  • Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during
           Apixaban or Dalteparin Therapy for Patients with Cancer

    • Free pre-print version: Loading...

      Authors: Cohen; Alexander T., Creeper, Katherine J., Alikhan, Raza, Er, Chaozer, Connors, Jean M., Huisman, Menno V., Munoz, Andres, Vescovo, Giorgio, Bauersachs, Rupert, Ageno, Walter, Agnelli, Giancarlo, Becattini, Cecilia
      Abstract: Background In patients with acute venous thromboembolism (VTE), the rates of recurrence and major bleeding are highest during the first weeks of anticoagulation. The CARAVAGGIO trial demonstrated noninferiority of apixaban to dalteparin for treatment of cancer-associated VTE without an increased risk of major bleeding. We compared the early time course of VTE recurrence and major bleeding events of apixaban compared with dalteparin at 7, 30, and 90 days of treatment in patients with cancer-associated VTE. Methods The study design of the CARAVAGGIO trial has been described. Eligible patients were randomly assigned to receive monotherapy with either apixaban or dalteparin for 6 months. The primary efficacy outcome was the incidence of objectively confirmed recurrent VTE. The primary safety outcome was major bleeding. Results In 1,155 patients, recurrent VTE after 7, 30, and 90 days occurred in 6 (1%), 15 (2.6%), and 27 (4.7%) patients in the apixaban arm versus 5 (0.9%), 20 (3.5%), and 36 (6.2%) patients respectively in the dalteparin arm. By day 7, 30, and 90, major bleeding events had occurred in 3 (0.5%), 9 (1.6%), and 16 (2.8%) patients in the apixaban group versus 5 (0.9%), 11 (1.9%), and 17 (2.9%) patients in the dalteparin group. Conclusion The frequencies of recurrent VTE and major bleeding events at 7, 30, and 90 days of apixaban compared with dalteparin were similar in patients with cancer-associated VTE. This supports the use of apixaban for the initiation and early phase of anticoagulant therapy in cancer-associated VTE.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-01-09T11:38:31+0100
      DOI: 10.1055/s-0043-1778642
       
  • Low Dietary Manganese and the Incidence of Venous Thromboembolism:
           Evidence for Minerals and Vitamins and the Other Comorbidities Linked to
           Venous Thromboembolism

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/a-2225-5513



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2024-01-09T11:35:30+0100
       
  • Comparison of Clinical Outcomes in Patients with Active Cancer Receiving
           Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study

    • Free pre-print version: Loading...

      Authors: Cohen; Alexander T., Wallenhorst, Christopher, Rivera, Marcella, Ay, Cihan, Schaefer, Bernhard, Abdelgawwad, Khaled, Psaroudakis, George, Brobert, Gunnar, Ekbom, Anders, Lee, Agnes Y. Y., Khorana, Alok A., Becattini, Cecilia, Carrier, Marc, Coleman, Craig I., Martinez, Carlos
      Pages: Abstract: Background In most patients with cancer-associated venous thromboembolism (CT), essentially those not at high risk of bleeding, guidelines recommend treatment with direct oral anticoagulants as an alternative to low-molecular-weight heparins (LMWHs). Population-based studies comparing these therapies are scarce. Objectives To compare the risk of venous thromboembolism (VTE) recurrences, significant bleeding, and all-cause mortality in patients with CT receiving rivaroxaban or LMWHs. Patients/Methods Using UK Clinical Practice Research Datalink data from 2013 to 2020, we generated a cohort of patients with first CT treated initially with either rivaroxaban or LMWH. Patients were observed 12 months for VTE recurrences, significant bleeds (major bleeds or clinically relevant nonmajor bleeding requiring hospitalization), and all-cause mortality. Overlap weighted sub-distribution hazard ratios (SHRs) compared rivaroxaban with LMWH in an intention-to-treat analysis. Results The cohort consisted of 2,259 patients with first CT, 314 receiving rivaroxaban, and 1,945 LMWH, mean age 72.4 and 66.9 years, respectively. In the 12-month observational period, 184 person-years following rivaroxaban and 1,057 following LMWH, 10 and 66 incident recurrent VTE events, 20 and 102 significant bleeds, and 10 and 133 deaths were observed in rivaroxaban and LMWH users, respectively. The weighted SHR at 12 months for VTE recurrences in rivaroxaban compared with LMWH were 0.80 (0.37–1.73); for significant bleeds 1.01 (0.57–1.81); and for all-cause mortality 0.49 (0.23–1.06). Conclusion Patients with CT, not at high risk of bleeding, treated with either rivaroxaban or LMWH have comparable effectiveness and safety outcomes. This supports the recommendation that rivaroxaban is a reasonable alternative to LMWH for the treatment of CT.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-04-08T12:53:05+01:00
      DOI: 10.1055/a-2259-0662
      Issue No: Vol. eFirst
       
  • Racial Differences in Ischemic and Hemorrhagic Stroke: An Ecological
           Epidemiological Study

    • Free pre-print version: Loading...

      Authors: Kang; Dong-Seon, Yang, Pil-Sung, Kim, Daehoon, Jang, Eunsun, Yu, Hee Tae, Kim, Tae-Hoon, Sung, Jung-Hoon, Pak, Hui-Nam, Lee, Moon-Hyoung, Lip, Gregory Y. H., Joung, Boyoung
      Pages: Abstract: Background This study aimed to evaluate racial differences in the incidence of stroke by conducting an ecological epidemiological study using UK Biobank and Korean nationwide data. Methods This study used individual data from the Korean National Health Insurance Service-Health Screening and UK Biobank, which included participants who underwent health examinations between 2006 and 2010. We included 112,750 East Asians (50.7% men, mean age: 52.6 years) and 210,995 Caucasians (44.7% men, mean age: 55.0 years) who were not diagnosed with atrial fibrillation, cardiovascular diseases, chronic kidney disease, chronic obstructive pulmonary disease, or cancer. The primary outcome was defined as a composite of ischemic and hemorrhagic stroke. Results East Asians tended to have a lower body mass index (23.7 vs. 26.4 kg/m2, p 
      Citation: Thromb Haemost ; : -
      PubDate: 2024-04-05T13:43:02+01:00
      DOI: 10.1055/a-2278-8769
      Issue No: Vol. eFirst
       
  • In-Hospital Pulmonary Arterial Embolism after Catheter Ablation of Over
           45,000 Cardiac Arrhythmias: Individualized Case Analysis of Multicentric
           Data

    • Free pre-print version: Loading...

      Authors: Doldi; Florian, Geßler, Nele, Anwar, Omar, Kahle, Ann-Kathrin, Scherschel, Katharina, Rath, Benjamin, Köbe, Julia, Lange, Philipp Sebastian, Frommeyer, Gerrit, Metzner, Andreas, Meyer, Christian, Willems, Stephan, Kuck, Karl-Heinz, Eckardt, Lars
      Pages: Abstract: Objective and Background Data on incidence of in-hospital pulmonary embolisms (PE) after catheter ablation (CA) are scarce. To gain further insights, we sought to provide new findings through case-based analyses of administrative data. Methods Incidences of PE after CA of supraventricular tachycardias (SVT), atrial fibrillation (AF), atrial flutter (AFlu), and ventricular tachycardias (VT) in three German tertiary centers between 2005 and 2020 were determined and coded by the G-DRG (German Diagnosis Related Groups System) and OPS (German Operation and Procedure Classification) systems. An administrative search was performed with a consecutive case-based analysis. Results Overall, 47,344 ablations were analyzed (10,037 SVT; 28,048 AF; 6,252 AFlu; 3,007 VT). PE occurred in 14 (0.03%) predominantly female (n = 9; 64.3%) patients with a mean age of 55.3 ± 16.9 years, body mass index 26.2 ± 5.1 kg/m2, and left ventricular ejection fraction of 56 ± 13.6%. PE incidences were 0.05% (n = 5) for SVT, 0.02% (n = 5) for AF, and 0.13% (n = 4) for VT ablations. No patient suffered PE after AFlu ablation. Five patients (35.7%) with PE after CA had no prior indication for oral anticoagulation (OAC). Preprocedural international normalized ratio in PE patients was 1.2 ± 0.5. Most patients with PE following CA presented with symptoms the day after the procedure (n = 9) after intraprocedural heparin application of 12,943.2 ± 5,415.5 IU. PE treatment included anticoagulation with either phenprocoumon (n = 5) or non-vitamin K-dependent OAC (n = 9). Two patients with PE died after VT/AF ablation, respectively. The remaining patients were discharged without sequels. Conclusion Over a 15-year period, incidence of PE after ablation is low, particularly low in patients with ablation for AF/AFlu. This is most likely due to stricter anticoagulation management in these patients compared with those receiving SVT/VT ablation procedures and could argue for continuation of OAC prior to ablation. Optimizing periprocedural anticoagulation management should be subject of further prospective trials.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-03-31T19:14:19+01:00
      DOI: 10.1055/s-0044-1785519
      Issue No: Vol. eFirst
       
  • Endothelial LAT1 (SLC7A5) Mediates S-Nitrosothiol Import and Modulates
           Respiratory Sequelae of Red Blood Cell Transfusion In Vivo

    • Free pre-print version: Loading...

      Authors: Zhu; Hongmei, Auten, Richard L., Whorton, Augustus Richard, Mason, Stanley Nicholas, Bock, Cheryl B., Kucera, Gary T., Kelleher, Zachary T., Vose, Aaron T., McMahon, Tim J.
      Pages: Abstract: Background Increased adhesivity of red blood cells (RBCs) to endothelial cells (ECs) may contribute to organ dysfunction in malaria, sickle cell disease, and diabetes. RBCs normally export nitric oxide (NO)-derived vascular signals, facilitating blood flow. S-nitrosothiols (SNOs) are thiol adducts formed in RBCs from precursor NO upon the oxygenation-linked allosteric transition in hemoglobin. RBCs export these vasoregulatory SNOs on demand, thereby regulating regional blood flow and preventing RBC–EC adhesion, and the large (system L) neutral amino acid transporter 1 (LAT1; SLC7A5) appears to mediate SNO export by RBCs. Methods To determine the role of LAT1-mediated SNO import by ECs generally and of LAT1-mediated SNO import by ECs in RBC SNO-dependent modulation of RBC sequestration and blood oxygenation in vivo, we engineered LAT1fl/fl; Cdh5-Cre+ mice, in which the putative SNO transporter LAT1 can be inducibly depleted (knocked down, KD) specifically in ECs (“LAT1ECKD”). Results We show that LAT1 in mouse lung ECs mediates cellular SNO uptake. ECs from LAT1ECKD mice (tamoxifen-induced LAT1fl/fl; Cdh5-Cre+) import SNOs poorly ex vivo compared with ECs from wild-type (tamoxifen-treated LAT1fl/fl; Cdh5-Cre−) mice. In vivo, endothelial depletion of LAT1 increased RBC sequestration in the lung and decreased blood oxygenation after RBC transfusion. Conclusion This is the first study showing a role for SNO transport by LAT1 in ECs in a genetic mouse model. We provide the first direct evidence for the coordination of RBC SNO export with EC SNO import via LAT1. SNO flux via LAT1 modulates RBC–EC sequestration in lungs after transfusion, and its disruption impairs blood oxygenation by the lung.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-03-22T10:58:55+0100
      DOI: 10.1055/s-0044-1782182
      Issue No: Vol. eFirst
       
  • The Lipid–Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition
           on Platelet Reactivity

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/s-0044-1782161



      Georg Thieme Verlag KG Stuttgart · New York

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2024-03-19T12:47:58+0100
      Issue No: Vol. eFirst
       
  • Racial Differences in Bleeding Risk: An Ecological Epidemiological Study
           Comparing Korea and United Kingdom Subjects

    • Free pre-print version: Loading...

      Authors: Kang; Dong-Seon, Yang, Pil-Sung, Kim, Daehoon, Jang, Eunsun, Yu, Hee Tae, Kim, Tae-Hoon, Sung, Jung Hoon, Pak, Hui-Nam, Lee, Moon-Hyoung, Lip, Gregory Y.H., Joung, Boyoung
      Pages: Abstract: Background This study aimed to evaluate racial differences in bleeding incidence by conducting an ecological epidemiological study using data from Korea and the United Kingdom. Methods We included healthy participants from the Korean National Health Insurance Service-Health Screening and the UK Biobank who underwent health examinations between 2006 and 2010 and had no comorbidities or history of medication use. Finally, 112,750 East Asians (50.7% men, mean age 52.6 years) and 210,995 Caucasians (44.7% men, mean age 55.0 years) were analyzed. The primary outcome was composed of intracranial hemorrhage (ICH) and bleeding from the gastrointestinal, respiratory, and genitourinary systems. Results During the follow-up, primary outcome events occurred in 2,110 East Asians and in 6,515 Caucasians. East Asians had a 38% lower 5-year incidence rate compared with Caucasians (3.88 vs. 6.29 per 1,000 person-years; incidence rate ratio [IRR]: 0.62, 95% confidence interval [CI]: 0.59–0.65). East Asians showed a lower incidence of major bleeding (IRR: 0.86, 95% CI: 0.81–0.91), bleeding from the gastrointestinal (IRR: 0.53, 95% CI: 0.49–0.56), and genitourinary systems (IRR: 0.49, 95% CI: 0.44–0.53) compared with Caucasians. The incidence rates of ICH (IRR: 3.20, 95% CI: 2.67–3.84) and bleeding from the respiratory system (IRR: 1.28, 95% CI: 1.11–1.47) were higher in East Asians. Notably, East Asians consuming alcohol ≥3 times/week showed a higher incidence of the primary outcome than Caucasians (IRR: 1.12, 95% CI: 1.01–1.25). Conclusion This ecological study revealed significant racial differences in bleeding incidence, influenced by anatomical sites and lifestyle habits, underscoring the need for tailored approaches in bleeding management based on race.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-03-08T12:44:36+0100
      DOI: 10.1055/a-2269-1123
      Issue No: Vol. eFirst
       
  • Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of
           Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert
           Consensus Paper

    • Free pre-print version: Loading...

      Authors: Harenberg; Job, Gosselin, Robert C., Cuker, Adam, Becattini, Cecilia, Pabinger, Ingrid, Poli, Sven, Weitz, Jeffrey, Ageno, Walter, Bauersachs, Rupert, Celap, Ivana, Choi, Philip, Douketis, James, Douxfils, Jonathan, Elalamy, Ismail, Falanga, Anna, Fareed, Jawed, Favaloro, Emmanuel J., Gerotziafas, Grigorios, Herkner, Harald, Hetjens, Svetlana, Heubner, Lars, Klamroth, Robert, Langer, Forian, Lip, Gregory Y. H., Grory, Brian Mac, Margetić, Sandra, Merrelaar, Anne, Pikta, Marika, Renne, Thomas, Schulman, Sam, Schwameis, Michael, Strbian, Daniel, Tafur, Alfonso, Vassart, Julie, Violi, Francesco, Walenga, Jeanine, Weiss, Christel
      Pages: Abstract: Background With the widespread use of direct oral anticoagulants (DOACs), there is an urgent need for a rapid assay to exclude clinically relevant plasma levels. Accurate and rapid determination of DOAC levels would guide medical decision-making to (1) determine the potential contribution of the DOAC to spontaneous or trauma-induced hemorrhage; (2) identify appropriate candidates for reversal, or (3) optimize the timing of urgent surgery or intervention. Methods and Results The DOAC Dipstick test uses a disposable strip to identify factor Xa- or thrombin inhibitors in a urine sample. Based on the results of a systematic literature search followed by an analysis of a simple pooling of five retrieved clinical studies, the test strip has a high sensitivity and an acceptably high negative predictive value when compared with levels measured with liquid chromatography tandem mass spectrometry or calibrated chromogenic assays to reliably exclude plasma DOAC concentrations ≥30 ng/mL. Conclusion Based on these data, a simple algorithm is proposed to enhance medical decision-making in acute care indications useful primarily in hospitals not having readily available quantitative tests and 24/7. This algorithm not only determines DOAC exposure but also differentiates between factor Xa and thrombin inhibitors to better guide clinical management.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-03-08T12:42:01+0100
      DOI: 10.1055/a-2261-1811
      Issue No: Vol. eFirst
       
  • Causal Effects of COVID-19 on the Risk of Thrombosis: A Two-Sample Mendel
           Randomization Study

    • Free pre-print version: Loading...

      Authors: Li; Zhengran, Zeng, Minghui, Wu, Tong, Wang, Zijin, Sun, Yuxin, Zhang, Ziran, Wu, Fanye, Chen, Zejun, Fu, Min, Meng, Fanke
      Pages: Abstract: Background Coronavirus disease 2019 (COVID-19) and thrombosis are linked, but the biomolecular mechanism is unclear. We aimed to investigate the causal relationship between COVID-19 and thrombotic biomarkers. Methods We used two-sample Mendelian randomization (MR) to assess the effect of COVID-19 on 20 thrombotic biomarkers. We estimated causality using inverse variance weighting with multiplicative random effect, and performed sensitivity analysis using weighted median, MR-Egger regression and MR Pleiotropy Residual Sum and Outlier (MR-PRESSO) methods. All the results were examined by false discovery rate (FDR) with the Benjamin and Hochberg method for this correction to minimize false positives. We used R language for the analysis. Results All COVID-19 classes showed lower levels of tissue factor pathway inhibitor (TFPI) and interleukin-1 receptor type 1 (IL-1R1). COVID-19 significantly reduced TFPI (odds ratio [OR] = 0.639, 95% confidence interval [CI]: 0.435–0.938) and IL-1R1 (OR = 0.603, 95% CI = 0.417–0.872), nearly doubling the odds. We also found that COVID-19 lowered multiple coagulation factor deficiency protein 2 and increased C–C motif chemokine 3. Hospitalized COVID-19 cases had less plasminogen activator, tissue type (tPA) and P-selectin glycoprotein ligand 1 (PSGL-1), while severe cases had higher mean platelet volume (MPV) and lower platelet count. These changes in TFPI, tPA, IL-1R1, MPV, and platelet count suggested a higher risk of thrombosis. Decreased PSGL-1 indicated a lower risk of thrombosis. Conclusion TFPI, IL-1R, and seven other indicators provide causal clues of the pathogenesis of COVID-19 and thrombosis. This study demonstrated that COVID-19 causally influences thrombosis at the biomolecular level.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-03-05T05:48:28+0100
      DOI: 10.1055/a-2263-8514
      Issue No: Vol. eFirst
       
  • ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil
           Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under
           Flow

    • Free pre-print version: Loading...

      Authors: Yada; Noritaka, Zhang, Quan, Bignotti, Antonia, Ye, Zhan, Zheng, X. Long
      Pages: Abstract: Background Neutrophil NETosis and neutrophil extracellular traps (NETs) play a critical role in pathogenesis of coronavirus disease 2019 (COVID-19)-associated thrombosis. However, the extents and reserve of NETosis, and potential of thrombus formation under shear in whole blood of patients with COVID-19 are not fully elucidated. Neither has the role of recombinant ADAMTS13 or caplacizumab on the accumulation of NETs and thrombus in COVID-19 patients' whole blood under shear been investigated. Methods Flow cytometry and microfluidic assay, as well as immunoassays, were employed for the study. Results We demonstrated that the percentage of H3Cit + MPO+ neutrophils, indicative of NETosis, was dramatically increased in patients with severe but not critical COVID-19 compared with that in asymptomatic or mild disease controls. Upon stimulation with poly [I:C], a double strain DNA mimicking viral infection, or bacterial shigatoxin-2, the percentage of H3Cit + MPO+ neutrophils was not significantly increased in the whole blood of severe and critical COVID-19 patients compared with that of asymptomatic controls, suggesting the reduction in NETosis reserve in these patients. Microfluidic assay demonstrated that the accumulation of NETs and thrombus was significantly enhanced in the whole blood of severe/critical COVID-19 patients compared with that of asymptomatic controls. Like DNase I, recombinant ADAMTS13 or caplacizumab dramatically reduced the NETs accumulation and thrombus formation under arterial shear. Conclusion Significantly increased neutrophil NETosis, reduced NETosis reserve, and enhanced thrombus formation under arterial shear may play a crucial role in the pathogenesis of COVID-19-associated coagulopathy. Recombinant ADAMTS13 or caplacizumab may be explored for the treatment of COVID-19-associated thrombosis.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-03-05T05:40:31+0100
      DOI: 10.1055/a-2253-9359
      Issue No: Vol. eFirst
       
  • No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A
           Two-Sample Mendelian Randomization Study

    • Free pre-print version: Loading...

      Authors: Du; Hong-Cheng, Zheng, Yun-Fei, Shen, Meng-Qi, Deng, Bai-Yang
      Pages: Abstract: Background Given the current debate in clinical research about the relationship between tobacco smoking and the risk of venous thromboembolism (VTE), a Mendelian randomization (MR) study was conducted aimed at elucidating the causal associations of current and past tobacco smoking with the risk of VTE, from the perspective of genetics. Methods Two-sample univariate and multivariable MR analyses were designed, using summary-level data from large genome-wide association studies involving European individuals. Causality was primarily assessed using multiplicative fixed-effects or random-effects model and inverse variance weighting, supplemented by MR–Egger regression, MR-PRESSO, Cochran's Q test, and leave-one-out for sensitivity analysis to test the reliability of the results. Results In the univariate MR analysis, no significant causal effects were found between current tobacco smoking and the risk of VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE). Similarly, no significant causal effects were found between past smoking and VTE, DVT, and PE. As for the multivariable MR analysis, results were consistent with univariate MR analysis, with no significant causal effect of either current or past tobacco smoking on the risk of VTE, DVT, and PE. Conclusion Evidence from both univariate and multivariable MR analyses demonstrated no significant causal relationships between current and past tobacco smoking and VTE, DVT, and PE. This contradicts positive correlations reported in some previous observational studies, which may be explained by other confounding factors. This provided genetic evidence for the conclusion reported in other observational studies that smoking did not affect VTE risk.
      Citation: Thromb Haemost ; : -
      PubDate: 2024-02-22T11:34:17+0100
      DOI: 10.1055/s-0044-1781425
      Issue No: Vol. eFirst
       
  • Neutrophil Extracellular Traps: Potential Prothrombotic State Markers and
           Therapeutic Targets for Atrial Fibrillation

    • Free pre-print version: Loading...

      Authors: Liu; Xing, Li, Xinjian, Xiong, Shenglin, Zhang, Haipeng, Suo, Rong, Zhang, Xu, Liu, Daiqi, Fu, Huaying, Liu, Tong, Li, Guangping
      Abstract: Background Recently, the mechanism of thrombogenesis has taken a new direction with the involvement of neutrophil extracellular traps (NETs). However, little is known about the relationship between NETs and thrombogenesis in atrial fibrillation (AF). Objective Our study aimed to evaluate NETs in AF patients and their potential association with thrombogenesis. In addition, we studied the effect of NETs on thrombogenesis in rat models. Methods A total of 125 AF patients and 172 controls were studied. Spontaneous echo contrast (SEC) was examined using transesophageal echocardiography to assess the prothrombotic state. We used rapid atrial pacing (RAP) rat models to study NETs' formation and their effects on thrombogenesis. The levels of NETs were analyzed by flow cytometry. To deeply understand the regulatory mechanism of NET formation, the transcriptional characteristics of the left atrial appendage (LAA) tissue from RAP rats were analyzed. Results We found that NETs were increased significantly in AF patients and positively correlated with SEC grades. And inserting the NET level could significantly enhance the predictivity of CHA2DS2-VASc scores for the AF prothrombotic state. In the RAP models, we observed that NET levels increased significantly in the LAA and promoted thrombosis. Meanwhile, we found that these changes could be suppressed by the NET formation inhibitor. Transcriptomic analysis of the LAA tissue from RAP rats suggested that RAP might stimulate the NET formation by promoting the expression of inflammatory cytokine and adhesion genes. Conclusion NETs may constitute useful thrombogenesis risk markers in AF patients and provide a potential therapeutic strategy for AF management.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-09-21T09:30:44+01:00
      DOI: 10.1055/s-0043-1774310
       
  • Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity
           and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI
           Trial

    • Free pre-print version: Loading...

      Authors: Ueki; Yasushi, Häner, Jonas D., Losdat, Sylvain, Gargiulo, Giuseppe, Shibutani, Hiroki, Bär, Sarah, Otsuka, Tatsuhiko, Kavaliauskaite, Raminta, Mitter, Vera R., Temperli, Fabrice, Spirk, David, Stortecky, Stefan, Siontis, George C. M., Valgimigli, Marco, Windecker, Stephan, Gutmann, Clemens, Koskinas, Konstantinos C., Mayr, Manuel, Räber, Lorenz
      Abstract: Objective The effect of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the effect of alirocumab added to high-intensity statin therapy on P2Y12 reaction unit (PRU) among AMI patients receiving dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor (ticagrelor or prasugrel). In addition, we assessed circulating platelet-derived noncoding RNAs (microRNAs and YRNAs). Methods This was a prespecified, powered, pharmacodynamic substudy of the PACMAN trial, a randomized, double-blind trial comparing biweekly alirocumab (150 mg) versus placebo in AMI patients undergoing percutaneous coronary intervention. Patients recruited at Bern University Hospital, receiving DAPT with a potent P2Y12 inhibitor, and adherent to the study drug (alirocumab or placebo) were analyzed for the current study. The primary endpoint was PRU at 4 weeks after study drug initiation as assessed by VerifyNow P2Y12 point-of-care assays. Results Among 139 randomized patients, the majority of patients received ticagrelor DAPT at 4 weeks (57 [86.4%] in the alirocumab group vs. 69 [94.5%] in the placebo group, p = 0.14). There were no significant differences in the primary endpoint PRU at 4 weeks between groups (12.5 [interquartile range, IQR: 27.0] vs. 19.0 [IQR: 30.0], p = 0.26). Consistent results were observed in 126 patients treated with ticagrelor (13.0 [IQR: 20.0] vs. 18.0 [IQR: 27.0], p = 0.28). Similarly, platelet-derived noncoding RNAs did not significantly differ between groups. Conclusion Among AMI patients receiving DAPT with a potent P2Y12 inhibitor, alirocumab had no significant effect on platelet reactivity as assessed by PRU and platelet-derived noncoding RNAs.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-09-11T14:32:32+01:00
      DOI: 10.1055/a-2156-7872
       
  • Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic
           Reviews with Meta-analyses of Randomized Controlled Trials with
           Homogeneous Design

    • Free pre-print version: Loading...

      Authors: Birocchi; Simone, Rocchetti, Matteo, Minardi, Alessandro, Podda, Gian Marco, Squizzato, Alessandro, Cattaneo, Marco
      Abstract: Background The value of guided therapy (GT) with anti-P2Y12 drugs in percutaneous coronary intervention (PCI) is unclear. Meta-analyses lumped together randomized controlled trials (RCTs) with heterogeneous designs, comparing either genotype-GT or platelet function test (PFT)-GT with unguided therapy. Some meta-analysis also included RCTs that did not explore GT, but included the effects of switching patients with high on-treatment platelet reactivity (HTPR) to alternative therapies (HTPR-Therapy). We performed three distinct systematic reviews/meta-analyses, each exploring only RCTs with homogeneous design. Methods MEDLINE, Embase, and Central databases were searched for RCTs testing genotype-GT, PFT-GT, or HTPR-Therapy in PCI-treated patients, through October 1, 2022. Two reviewers extracted the data. Risk ratios (RRs) (95% confidence intervals) were calculated. Primary outcomes were major bleedings (MBs) and major adverse cardiovascular events (MACE). Results In seven genotype-GT RCTs, RRs were: MB, 1.06 (0.73–1.54; p = 0.76); MACE, 0.65 (0.47–0.91; p = 0.01), but significant risk reduction was observed in RCTs performed in China (0.30, 0.16–0.54; p 
      Citation: Thromb Haemost ; : -
      PubDate: 2023-09-05T13:42:12+01:00
      DOI: 10.1055/a-2149-4344
       
  • Vaccine-Induced Immune Thrombotic Thrombocytopenia Two Years Later: Should
           It Still Be on the Scientific Agenda'

    • Free pre-print version: Loading...

      Authors: Petito; Eleonora, Gresele, Paolo
      Abstract: Vaccine-induced immune thrombotic thrombocytopenia (VITT) was recognized around 2 years ago, at the beginning of the anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination campaign, as a rare but life-threatening complication of adenoviral vector vaccines. Two years later, the coronavirus disease 2019 (COVID-19) pandemic has been tamed, although not defeated, and the vaccines provoking VITT have been abandoned in most high-income countries, thus why should we still speak about VITT' Because a significant fraction of the world population has not been vaccinated yet, especially in low/middle-income countries that can only afford adenoviral vector-based vaccines, because the adenoviral vector platform is being used for the development of a large series of new vaccines for other transmissible diseases, and lastly because there are some clues suggesting that VITT may not be exclusive to anti-SARS-CoV-2 vaccines. Therefore, a deep understanding of this new syndrome is highly warranted as well as the awareness that we still miss some crucial insight into its pathophysiology and on some aspects of its management. This snapshot review aims to portray our knowledge on VITT, focusing on its clinical presentation, pathophysiological insight, diagnostic and management strategies, and to pinpoint the main unmet needs, highlighting the aspects on which research should focus in the near future.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-08-07T07:42:42+01:00
      DOI: 10.1055/a-2107-0891
       
  • Inverse Association of Lipoprotein(a) on Long-Term Bleeding Risk in
           Patients with Coronary Heart Disease: Insight from a Multicenter Cohort in
           Asia

    • Free pre-print version: Loading...

      Authors: Wang; Peizhi, Yuan, Deshan, Zhao, Xueyan, Zhu, Pei, Guo, Xiaogang, Jiang, Lin, Xu, Na, Wang, Zhifang, Liu, Ru, Wang, Qingsheng, Chen, Yan, Zhang, Yongzhen, Xu, Jingjing, Liu, Zhenyu, Song, Ying, Zhang, Zheng, Yao, Yi, Feng, Yingqing, Tang, Xiaofang, Wang, Xiaozeng, Gao, Runlin, Han, Yaling, Yuan, Jinqing
      Abstract: Background Lipoprotein(a), or Lp(a), has been recognized as a strong risk factor for atherosclerotic cardiovascular disease. However, the relationship between Lp(a) and bleeding remains indistinct, especially in the secondary prevention population of coronary artery disease (CAD). This investigation aimed to evaluate the association of Lp(a) with long-term bleeding among patients with CAD. Methods Based on a prospective multicenter cohort of patients with CAD consecutively enrolled from January 2015 to May 2019 in China, the current analysis included 16,150 participants. Thus, according to Lp(a) quintiles, all subjects were divided into five groups. The primary endpoint was bleeding at 2-year follow-up, and the secondary endpoint was major bleeding at 2-year follow-up. Results A total of 2,747 (17.0%) bleeding and 525 (3.3%) major bleeding were recorded during a median follow-up of 2.0 years. Kaplan–Meier survival analysis showed the highest bleeding incidence in Lp(a) quintile 1, compared with patients in Lp(a) quintiles 2 to 5 (p 
      Citation: Thromb Haemost ; : -
      PubDate: 2023-07-24T11:53:32+01:00
      DOI: 10.1055/s-0043-1771188
       
  • Low HDL Cholesterol Is Associated with Reduced Bleeding Risk in Patients
           Who Underwent PCI: Findings from the PRACTICE Study

    • Free pre-print version: Loading...

      Authors: Zheng; Ying-Ying, Wu, Ting-Ting, Hou, Xian-Geng, Yang, Yi, Yang, Hai-Tao, Pan, Ying, Xiu, Wen-Juan, Ma, Xiang, Ma, Yi-Tong, Yang, Xin-Ling, Xie, Xiang
      Abstract: Background We sought to examine the dose–response relationship between high-density lipoprotein cholesterol (HDL-C) and bleeds in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Methods All the 15,250 participants were from the Personalized Antiplatelet Therapy According to CYP2C19 Genotype in Coronary Artery Disease (PRACTICE) study, which is a large, single-center, prospective cohort study based on case records and a follow-up registry performed in the First Affiliated Hospital of Xinjiang Medical University from December 2016 to October 2021. We divided all the patients into five groups according to their HDL-C levels: the ≤35 mg/dL group (n = 4,732), 35 to 45 mg/dL group (n = 6,049), 45 to 55 mg/dL group (n = 2,826), 55 and 65 mg/dL group (n = 1,117), and>65 mg/dL group (n = 526). The incidence of bleeds, mortality, ischemic events, and net adverse clinical events (NACEs) among the five groups was compared. Results A total of 713 bleeds, 1,180 ischemic events, 456 deaths, and 1,893 NACEs were recorded during the up to 60-month follow-up period. After adjusting for confounders, we observed a nonlinear relation for bleeds, with the highest risk at intermediate HDL-C levels (45–55 mg/dL). We also identified a dose–response relationship for ischemic events. A threshold value of HDL-C ≤35 mg/dL (adjusted hazard ratio = 0.560, 95% confidence interval: 0.360–0.872, p = 0.010) was associated with a decreased risk for bleeds in the multivariable Cox regression model. The results were consistent in multiple sensitivity analyses and propensity score-matching analysis. Conclusion In the present study, a nonlinear association was identified between HDL-C levels and bleeds in CAD patients who underwent PCI, with a higher risk at intermediate levels. However, further multicenter studies are warranted.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-07-08T12:09:31+01:00
      DOI: 10.1055/a-2104-1693
       
  • Gaining Insights into Inherited Bleeding Disorders of Complex Etiology in
           Pediatric Patients: Whole-Exome Sequencing as First-Line Investigation
           Tool

    • Free pre-print version: Loading...

      Authors: Bandini; Perla, Borràs, Nina, Berrueco, Ruben, Gassiot, Susanna, Martin-Fernandez, Laura, Sarrate, Edurne, Comes, Natàlia, Ramírez, Lorena, Hobeich, Carlos, Vidal, Francisco, Corrales, Irene
      Pages: Abstract: Introduction Investigation of the molecular basis of inherited bleeding disorders (IBD) is mostly performed with gene panel sequencing. However, the continuous discovery of new related genes underlies the limitation of this approach. This study aimed to identify genetic variants responsible for IBD in pediatric patients using whole-exome sequencing (WES), and to provide a detailed description and reclassification of candidate variants. Material and Methods WES was performed for 18 pediatric patients, and variants were filtered using a first-line list of 290 genes. Variant prioritization was discussed in a multidisciplinary team based on genotype-phenotype correlation, and segregation studies were performed with available family members. Results The study identified 22 candidate variants in 17 out of 18 patients (94%). Eleven patients had complete genotype-phenotype correlation, resulting in a diagnostic yield of 61%, 5 (28%) were classified as partially solved, and 2 (11%) remained unsolved. Variants were identified in platelet (ACTN1, ANKRD26, CYCS, GATA1, GFI1B, ITGA2, NBEAL2, RUNX1, SRC, TUBB1), bleeding (APOLD1), and coagulation (F7, F8, F11, VWF) genes. Notably, 9 out of 22 (41%) variants were previously unreported. Variant pathogenicity was assessed according to the American College of Medical Genetics and Genomics guidelines and reclassification of three variants based on family segregation evidence, resulting in the identification of 10 pathogenic or likely pathogenic variants, 6 variants of uncertain significance, and 6 benign or likely benign variants. Conclusion This study demonstrated the high potential of WES in identifying rare molecular defects causing IBD in pediatric patients, improving their management, prognosis, and treatment, particularly for patients at risk of malignancy and/or bleeding due to invasive procedures.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-29T12:27:11+0100
      DOI: 10.1055/s-0043-1778070
      Issue No: Vol. eFirst
       
  • Outcomes of Patients with a Mechanical Heart Valve and Poor
           Anticoagulation Control on Warfarin

    • Free pre-print version: Loading...

      Authors: Johansson; Isabelle, Benz, Alexander P., Kovalova, Tanya, Balasubramanian, Kumar, Fukakusa, Bianca, Lynn, Matthew J., Nair, Nikhil, Sikder, Omaike, Patel, Kashyap, Gayathri, Sai, Robinson, Marlene, Hardy, Colin, Tyrwhitt, Jessica, Schulman, Sam, Eikelboom, John W., Connolly, Stuart J.
      Pages: Abstract: Background Patients with a mechanical heart valve (MHV) require oral anticoagulation. Poor anticoagulation control is thought to be associated with adverse outcomes, but data are limited. Objective To assess the risks of clinical outcomes in patients with a MHV and poor anticoagulation control on warfarin. Patients/Methods We conducted a retrospective study of consecutive patients undergoing MHV implantation at a tertiary care center (2010–2019). Primary outcome was a composite of ischemic stroke, systemic embolism, or prosthetic valve thrombosis. Major bleeding and death were key secondary outcomes. We constructed multivariable regression models to assess the association between time in therapeutic range (TTR) on warfarin beyond 90 days after surgery with outcomes. Results We included 671 patients with a MHV (80.6% in aortic, 14.6% in mitral position; mean age 61 years, 30.3% female). Median follow-up was 4.9 years, mean TTR was 62.5% (14.5% TTR 60%). Overall rates of the primary outcome, major bleeding, and death were 0.73, 1.41, and 1.44 per 100 patient-years. Corresponding rates for patients with TTR
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-29T12:21:57+0100
      DOI: 10.1055/s-0043-1777827
      Issue No: Vol. eFirst
       
  • Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/a-2205-0014



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2023-12-29T12:19:35+0100
      Issue No: Vol. eFirst
       
  • Ethnic Differences in Thrombotic Profiles of Acute Coronary Syndrome
           Patients and Relationship to Cardiovascular Outcomes: A Comparison of East
           Asian and White subjects

    • Free pre-print version: Loading...

      Authors: Suh; Jung-Won, Memtsas, Vassilios, Gue, Ying X, Cho, Hyoung-Won, Lee, Wonjae, Kang, Si-Hyuck, Gorog, Diana A.
      Pages: Abstract: Background East Asians (EAs), compared to white Caucasians (W), have a lower risk of ischemic heart disease and a higher risk of bleeding with antithrombotic medications. The underlying mechanisms are incompletely understood. Objectives We sought to compare thrombotic profiles of EA and W patients with myocardial infarction (MI) and relate these to cardiovascular outcomes. Methods In a prospective study in the United Kingdom and Korea, blood samples from patients (n = 515) with ST- or non-ST-elevation MI (STEMI and NSTEMI) were assessed using the Global Thrombosis Test, measuring thrombotic occlusion (OT) and endogenous fibrinolysis (lysis time [LT]). Patients were followed for 1 year for major adverse cardiovascular events (MACE) and bleeding. Results EA patients showed reduced OT (longer OT) compared to W (646 seconds [470–818] vs. 436 seconds [320–580], p 
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-29T12:10:20+0100
      DOI: 10.1055/s-0043-1777794
      Issue No: Vol. eFirst
       
  • Association and Pathways between Dietary Manganese Intake and Incident
           Venous Thromboembolism

    • Free pre-print version: Loading...

      Authors: Huang; Yu, Zhang, Yanjun, Yang, Sisi, Xiang, Hao, Zhou, Chun, Ye, Ziliang, Liu, Mengyi, He, Panpan, Zhang, Yuanyuan, Gan, Xiaoqin, Qin, Xianhui
      Pages: Abstract: Background The association between dietary manganese (Mn) intake and the risk of venous thromboembolism (VTE) remains unknown. We aimed to investigate the associations of dietary Mn intake with incident VTE, and the underlying mediating roles of obesity markers (body mass index [BMI] and waist circumference), hemorheological parameters (red cell distribution width [RDW], platelet count [PLT], and mean platelet volume [MPV]), and inflammatory biomarkers (C-reactive protein [CRP] and white blood cell count [WBC]) in this association. Methods A total of 202,507 adults from the UK Biobank with complete dietary data and without VTE at baseline were included. Dietary information was collected by the online 24-hour diet recall questionnaires (Oxford WebQ). The primary outcome was incident VTE, a composite of incident deep vein thrombosis (DVT) and pulmonary embolism (PE). Results During a median follow-up of 11.6 years, 4,750 participants developed incident VTE. Overall, there were significantly inverse relationships of dietary Mn intake with incident VTE (per 1 mg/day increment; adjusted hazard ratio [HR]: 0.92; 95% confidence interval [CI]: 0.90–0.95), incident DVT (per 1 mg/day increment; adjusted HR: 0.93; 95% CI: 0. 90–0.96), and incident PE (per 1 mg/day increment; adjusted HR: 0.91; 95% CI: 0.88–0.95). BMI, waist circumference, RDW, CRP, and WBC significantly mediated the association between dietary Mn intake and incident VTE, with the mediated proportions of 36.0, 36.5, 4.2, 4.3, and 1.6%, respectively. However, MPV and PLT did not significantly mediate the association. Conclusion Our study shows that dietary Mn intake was inversely associated with incident VTE. The inverse association was mainly mediated by obesity, followed by inflammatory biomarkers and RDW. Our findings are just hypothesis-generating, and further confirmation of our findings in more studies is essential.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-27T08:48:53+0100
      DOI: 10.1055/a-2213-8939
      Issue No: Vol. eFirst
       
  • Cost-Effectiveness of Performing Reference Ultrasonography in Patients
           with Deep Vein Thrombosis

    • Free pre-print version: Loading...

      Authors: de Jong; Cindy M. M., van den Hout, Wilbert B., van Dijk, Christel E., Heim, Noor, van Dam, Lisette F., Dronkers, Charlotte E. A., Gautam, Gargi, Ghanima, Waleed, Gleditsch, Jostein, von Heijne, Anders, Hofstee, Herman M. A., Hovens, Marcel M. C., Huisman, Menno V., Kolman, Stan, Mairuhu, Albert T. A., van Mens, Thijs E., Nijkeuter, Mathilde, van de Ree, Marcel A., van Rooden, Cornelis J., Westerbeek, Robin E., Westerink, Jan, Westerlund, Eli, Kroft, Lucia J. M., Klok, Frederikus A.
      Pages: Abstract: Background The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) with compression ultrasonography (CUS) may be hindered by residual intravascular obstruction after previous DVT. A reference CUS, an additional ultrasound performed at anticoagulant discontinuation, may improve the diagnostic work-up of suspected recurrent ipsilateral DVT by providing baseline images for future comparison. Objectives To evaluate the cost-effectiveness of routinely performing reference CUS in DVT patients. Methods Patient-level data (n = 96) from a prospective management study (Theia study; NCT02262052) and claims data were used in a decision analytic model to compare 12 scenarios for diagnostic management of suspected recurrent ipsilateral DVT. Estimated health care costs and mortality due to misdiagnosis, recurrent venous thromboembolism, and bleeding during the first year of follow-up after presentation with suspected recurrence were compared. Results All six scenarios including reference CUS had higher estimated 1-year costs (€1,763–€1,913) than the six without reference CUS (€1,192–€1,474). Costs were higher because reference CUS results often remained unused, as 20% of patients (according to claims data) would return with suspected recurrent DVT. Estimated mortality was comparable in scenarios with (14.8–17.9 per 10,000 patients) and without reference CUS (14.0–18.5 per 10,000). None of the four potentially most desirable scenarios included reference CUS. Conclusion One-year health care costs of diagnostic strategies for suspected recurrent ipsilateral DVT including reference CUS are higher compared to strategies without reference CUS, without mortality benefit. These results can inform policy-makers regarding use of health care resources during follow-up after DVT. From a cost-effectiveness perspective, the findings do not support the routine application of reference CUS.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-27T08:34:58+0100
      DOI: 10.1055/a-2213-9230
      Issue No: Vol. eFirst
       
  • Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital
           COVID-19: A Meta-analysis of Two Placebo-Controlled Trials

    • Free pre-print version: Loading...

      Authors: Hsia; Judith, Spyropoulos, Alex C., Piazza, Gregory, Weng, Stephen, Dunne, Michael W., Lipardi, Concetta, Barnathan, Elliot S., Bonaca, Marc P.
      Pages: Abstract: Background We conducted a prespecified meta-analysis of two randomized, placebo-controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute coronavirus disease 2019 (COVID-19). Individually, the trials had limited power to detect a treatment effect due to recruitment stopping ahead of plan. Material and Methods The statistical analysis plan for the meta-analysis was finalized before unblinding of PREVENT-HD, the larger of the two trials. Pooled risk ratios and pooled risk differences along with the two-sided 95% confidence intervals were calculated using random-effect models. Results Rivaroxaban did not reduce the occurrence of either the primary prespecified endpoint, a composite of symptomatic arterial and venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, all-cause hospitalization, and all-cause mortality (risk difference: 0.0044; 95% confidence interval: −0.0263, 0.0175; p = 0.69 for pooled risk difference) or the secondary endpoint of all-cause hospitalization (p = 0.76). Although thrombotic events were infrequent, pooled analysis did reveal that rivaroxaban reduced arterial and venous thrombotic events (placebo 6 events, rivaroxaban 0 events; pooled risk difference: −0.0068; 95% confidence interval: −0.0132, −0.0006; p = 0.03). In the pooled studies, only one major bleeding event was observed in a rivaroxaban-allocated patient with no critical site or fatal bleeding events. Conclusion Although this meta-analysis does not support antithrombotic prophylaxis with rivaroxaban in a broad prehospital population with acute COVID-19, the prevention of arterial and venous thrombotic events among rivaroxaban-allocated patients is consistent with the known thromboprophylactic effect of the drug in medically ill patients.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-21T08:27:21+0100
      DOI: 10.1055/a-2216-5848
      Issue No: Vol. eFirst
       
  • Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary
           Intervention

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/a-2216-5263



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2023-12-18T12:41:30+0100
      Issue No: Vol. eFirst
       
  • Atherosclerotic Autoantigen ALDH4A1 as a Novel Immunological Indicator for
           

    • Free pre-print version: Loading...

      Authors: Li; Jiannan, Chen, Runzhen, Zhou, Jinying, Wang, Ying, Zhao, Xiaoxiao, Liu, Chen, Zhou, Peng, Chen, Yi, Song, Li, Li, Nan, Yan, Hongbing, Zhao, Hanjun
      Pages: Abstract: Objective Aldehyde dehydrogenase 4A1 (ALDH4A1) was recently reported to be a novel autoantigen of atherosclerosis. However, its role in different phenotypes of acute coronary syndrome remains unclear. Herein, we planned to explore the circulating and regional expression of ALDH4A1 in patients with plaque rupture (PR) and plaque erosion (PE) determined by optical coherence tomography (OCT). Methods and Results After applying the inclusion and exclusion criteria, a prospective series of 312 patients with ST segment elevated myocardial infarction (STEMI), including 161 patients with PR and 151 patients with PE determined by OCT, were enrolled for plasma ALDH4A1 testing. In addition, ALDH4A1 was quantified using immunofluorescence in aspirated coronary thrombus samples obtained from 31 patients with PR and 25 patients with PE. In addition, we established an atherosclerosis mouse model and analyzed the distribution of ALDH4A1 expression in different mouse organs. Furthermore, we compared the level of ALDH4A1 in the spleen and carotid artery between Apoe−/− and C57 mice. The results showed that the plasma level of ALDH4A1 was significantly higher in STEMI patients with PE than in those with PR (4.6 ng/mL [2.2–8.7] vs. 3.5 ng/mL [1.6–5.6] p = 0.005). The expression of ALDH4A1 in aspirated coronary thrombi was also significantly higher in patients with PE than in those with PR (mean gray value: 32.0 [23.6–40.6] vs. 16.8 [14.0–24.5], p 
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-18T12:40:27+0100
      DOI: 10.1055/s-0043-1777265
      Issue No: Vol. eFirst
       
  • Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic
           Thrombocytopenia: A Systematic Review of Published Cases

    • Free pre-print version: Loading...

      Authors: Clerici; Bianca, Pontisso, Eleonora, Aloise, Chiara, Peroni, Benedetta, Perricone, Rosaria, Pisetta, Chiara, Scavone, Mariangela, Birocchi, Simone, Podda, Gian Marco
      Pages: Abstract: Introduction Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear. Methods We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case reports and case series providing nonaggregate data of VITT patients. Accurate VITT diagnosis required fulfillment of the following criteria: (1) endorsement by the authors, (2) consistent vaccine type and timing, (3) presence of thrombocytopenia and thrombosis, (4) detection of anti-platelet factor 4 antibodies. Data are presented as frequencies with 95% confidence intervals (CIs) calculated with the exact binomial method. Results We retrieved 143 eligible studies, describing 366 patients. Of 647 thrombotic events, 53% (95% CI: 49–56) were venous thromboses at unusual sites and 30% (95% CI: 27–34) were cerebral venous sinus thromboses (CVSTs). The ratio of venous-to-arterial events was 4.1. Thromboses in most sites were associated with at least another thrombotic event, with the exception of CVST and CNS arterial thrombosis (isolated in 49 and 39% of cases, respectively). Bleeding occurred in 36% (95% CI: 31–41) of patients; 68% (95% CI: 59–75) of bleeding events were intracranial hemorrhages (ICHs). Overall mortality was 24% (95% CI: 19–29), and 77% (95% CI: 58–90) in patients with isolated CVST complicated by ICH. Conclusion VITT displays a venous-to-arterial thrombosis ratio comparable to heparin-induced thrombocytopenia. However, VITT is characterized by a higher prevalence of CVST and ICH, which contribute to the increased bleeding frequency and mortality.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-18T06:26:53+0100
      DOI: 10.1055/s-0043-1777134
      Issue No: Vol. eFirst
       
  • Circulating Cytokines and Venous Thromboembolism: A Bidirectional
           Two-Sample Mendelian Randomization Study

    • Free pre-print version: Loading...

      Authors: Hu; Teng, Su, Pengpeng, Yang, Fangkun, Ying, Jiajun, Chen, Yu, Cui, Hanbin
      Pages: Abstract: Background Epidemiological evidence has linked circulating cytokines to venous thromboembolism (VTE). However, it remains uncertain whether these associations are causal due to confounding factors or reverse causality. We aim to explore the causality between circulating cytokines and VTE, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods In the current bidirectional Mendelian randomization (MR) study, instrumental variables of 41 circulating cytokines were obtained from the genome-wide association study meta-analyses (8,293 individuals). Summary statistics for the association of VTE (17,048 cases and 325,451 controls), DVT (8,077 cases and 295,014 controls), and PE (8,170 cases and 333,487 controls) were extracted from the FinnGen Study. A multivariable MR study was conducted to adjust for potential confounders. The inverse-variance weighted method was employed as the main analysis, and comprehensive sensitivity analyses were conducted in the supplementary analyses. Results The MR analysis indicated stromal cell-derived factor-1α was suggestively associated with a reduced risk of VTE (odds ratio [OR]: 0.90; 95% confidence interval [CI]: 0.81–0.99; p = 0.033) and DVT (OR: 0.85; 95% CI: 0.75–0.97; p = 0.015). In addition, suggestive association of granulocyte colony-stimulating factor with PE (OR: 1.20; 95% CI: 1.06-1.37; p = 0.005) was observed. Multivariable MR analysis showed that the effect of cytokines on VTE was partly mediated through hemoglobin A1c and systolic blood pressure. Reverse MR analysis revealed that VTE was linked to decreased levels of several cytokines. Conclusion We provide suggestive genetic evidence supporting the bidirectional causal effect between circulating cytokines and VTE, highlighting the importance of targeting circulating cytokines to reduce the incidence of VTE.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-12-18T06:14:08+0100
      DOI: 10.1055/s-0043-1777351
      Issue No: Vol. eFirst
       
  • Ser252Asn Mutation Introduces a New N-Linked Glycosylation Site and Causes
           Type IIb Protein C Deficiency

    • Free pre-print version: Loading...

      Authors: Zhou; Shijie, Wu, Xi, Song, Ying, Li, Lei, Shi, Chunli, Lai, Zhe, Ding, Qiulan, Wu, Wenman, Dai, Jing, Wang, Xuefeng, Lu, Yeling
      Pages: Abstract: Background: Protein C (PC) is a vitamin K-dependent anticoagulant serine protease zymogen which upon activation by the thrombin–thrombomodulin (TM) complex downregulates the coagulation cascade by degrading cofactors Va and VIIIa by limited proteolysis. We identified a thrombosis patient who carried a heterozygous mutation c.881G > A, p.Ser252Asn (S252N) in PROC. This mutation was originally described in a report of novel mutations in patients presenting with defective PC anticoagulant activity in Paris. The research identified PC-S252N (the “Paris” mutation) in a propositus and her family members and highlighted the critical role of Ser252 in the anticoagulation process of activated PC (APC). Material and Methods: We expressed the PC-S252N mutant in mammalian cells and characterized the properties in coagulation assays to decipher the molecular basis of anticoagulant defect of this mutation. Results: We demonstrated that PC-S252N had a diminished ability to TM binding, which resulted in its impaired activation by the thrombin-TM complex. However, APC-S252N exhibited a slightly stronger cleavage capacity for the chromogenic substrate. Meanwhile, the catalytic activity of APC-S252N toward FVa was significantly reduced. Sequence analysis revealed that Ser252 to Asn substitution introduced a new potential N-linked glycosylation site (252NTT254) in the catalytic domain of PC, which adversely affected both the activation process of PC and anticoagulant activity of APC. Conclusion: The new N-glycosylation site (252NTT254) resulting from the mutation of Ser252 to Asn252 in PROC affects the overall structure of the protease, thereby adversely affecting the anticoagulant function of protein C. This modification has a negative impact on both TM-promoted activation of protein C and APC cleavage of FVa, ultimately leading to thrombosis in the patient.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-11-27T07:22:05+0100
      DOI: 10.1055/s-0043-1777133
      Issue No: Vol. eFirst
       
  • Persistent and Late-Onset Disseminated Intravascular Coagulation Are
           Closely Related to Poor Prognosis in Patients with Sepsis

    • Free pre-print version: Loading...

      Authors: Matsuoka; Tadashi, Yamakawa, Kazuma, Iba, Toshiaki, Homma, Koichiro, Sasaki, Junichi
      Pages: Abstract: Background Septic-associated disseminated intravascular coagulation (DIC) is heterogeneous regarding prognosis and responsiveness to anticoagulant therapy. Objectives To investigate the relationship between the timing of development and recovery of DIC, its prognosis, and the difference in response to anticoagulant therapy in sepsis-associated DIC patients. Methods This study was performed with a dataset from a multicenter nationwide retrospective cohort study (J-Septic DIC registry) in Japan between 2011 and 2013 to reveal the subgroup “high risk of death in DIC” and investigate the relationship between anticoagulant use and mortality. Patients were assigned to four groups based on the International Society on Thrombosis and Haemostasis-overt DIC status at days 1 and 3: non-DIC (−/−), early-recovered DIC (+/−), late-onset DIC (−/+), and persistent DIC (+/+). Results A total of 1,922 patients were included. In-hospital mortality in persistent and late-onset DIC patients was significantly higher than in patients with non-DIC and early-recovered DIC. This finding indicates that persistent DIC and late-onset DIC were a poor-prognosis subgroup, “high-risk” DIC. Meanwhile, patients with high-risk DIC treated with anticoagulants had significantly better outcomes than those without anticoagulants after adjusting for confounding factors. Conclusion This study showed that individuals with a high risk of death, persistent DIC, and late-onset DIC were a poor-prognostic subgroup in septic DIC; however, high-risk DIC is also a subgroup that can obtain more benefits from anticoagulant therapy.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-11-21T12:00:24+0100
      DOI: 10.1055/a-2196-3630
      Issue No: Vol. eFirst
       
  • Addendum: Sex as a Risk Factor for Atrial Fibrillation-Related Stroke

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/s-0043-1777123



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2023-11-21T11:55:42+0100
      Issue No: Vol. eFirst
       
  • Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone
           Therapy

    • Free pre-print version: Loading...

      Authors: Dix; Caroline, Moloney, Mollie, Tran, Huyen A., McFadyen, James D.
      Pages: Abstract: Gender-affirming therapy involves the use of hormones to develop the physical characteristics of the identified gender and suppressing endogenous sex hormone production. Venous thromboembolism (VTE) is a known risk of exogenous estrogen therapy, and while evidence of VTE risk among transgender women using modern gender-affirming hormone therapy (GAHT) is still emerging, it is thought to affect up to 5% of transgender women. Historically, GAHT was associated with a high risk of VTE; however, modern preparations are less thrombogenic mainly due to significantly lower doses used as well as different preparations. This review presents the available literature regarding the following four topics: (1) risk of VTE among transgender women receiving estradiol GAHT, (2) how the route of administration of estradiol affects the VTE risk, (3) perioperative management of GAHT, (4) VTE risk among adolescents on GAHT. There is a need for large, longitudinal studies of transgender women using GAHT to further characterize VTE risk and how this is affected by factors such as patient age, duration of GAHT use, tobacco use, body mass index, and comorbidities. Future studies in these areas could inform the development of clinical guidelines to improve the care of transgender people.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-11-02T19:38:50+0100
      DOI: 10.1055/a-2188-8898
      Issue No: Vol. eFirst
       
  • Are NETs a Novel, Exciting, Thrombosis Risk Marker'

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/a-2187-0645



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2023-11-02T19:32:54+0100
      Issue No: Vol. eFirst
       
  • Differential Effects of Erythropoietin Administration and Overexpression
           on Venous Thrombosis in Mice

    • Free pre-print version: Loading...

      Authors: Stockhausen; Sven, Kilani, Badr, Schubert, Irene, Steinsiek, Anna-Lena, Chandraratne, Sue, Wendler, Franziska, Eivers, Luke, von Brühl, Marie-Luise, Massberg, Steffen, Ott, Ilka, Stark, Konstantin
      Pages: Abstract: Background Deep vein thrombosis (DVT) is a common condition associated with significant mortality due to pulmonary embolism. Despite advanced prevention and anticoagulation therapy, the incidence of venous thromboembolism remains unchanged. Individuals with elevated hematocrit and/or excessively high erythropoietin (EPO) serum levels are particularly susceptible to DVT formation. We investigated the influence of short-term EPO administration compared to chronic EPO overproduction on DVT development. Additionally, we examined the role of the spleen in this context and assessed its impact on thrombus composition. Methods We induced ligation of the caudal vena cava (VCC) in EPO-overproducing Tg(EPO) mice as well as wildtype mice treated with EPO for two weeks, both with and without splenectomy. The effect on platelet circulation time was evaluated through FACS analysis, and thrombus composition was analyzed using immunohistology. Results We present evidence for an elevated thrombogenic phenotype resulting from chronic EPO overproduction, achieved by combining an EPO-overexpressing mouse model with experimental DVT induction. This increased thrombotic state is largely independent of traditional contributors to DVT, such as neutrophils and platelets. Notably, the pronounced prothrombotic effect of red blood cells (RBCs) only manifests during chronic EPO overproduction and is not influenced by splenic RBC clearance, as demonstrated by splenectomy. In contrast, short-term EPO treatment does not induce thrombogenesis in mice. Consequently, our findings support the existence of a differential thrombogenic effect between chronic enhanced erythropoiesis and exogenous EPO administration. Conclusion Chronic EPO overproduction significantly increases the risk of DVT, while short-term EPO treatment does not. These findings underscore the importance of considering EPO-related factors in DVT risk assessment and potential therapeutic strategies.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-10-16T09:55:37+01:00
      DOI: 10.1055/s-0043-1775965
      Issue No: Vol. eFirst
       
  • Strategies for Tailored Antiplatelet Therapy after Percutaneous Coronary
           Intervention: Unraveling Complexities, Embracing Nuances

    • Free pre-print version: Loading...

      Thromb Haemost
      DOI: 10.1055/a-2177-4220



      Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

      Artikel in Thieme eJournals:
      Inhaltsverzeichnis     Volltext

      Thromb Haemost ; : -2023-10-09T13:53:12+01:00
      Issue No: Vol. eFirst
       
  • Macrophage Ferroptosis Promotes MMP2/9 Overexpression Induced by Hemin in
           Hemorrhagic Plaque

    • Free pre-print version: Loading...

      Authors: Li; Bicheng, Lu, Minqiao, Wang, Hui, Sheng, Siqi, Guo, Shuyuan, Li, Jia, Tian, Ye
      Pages: Abstract: Background Intra-plaque hemorrhage (IPH) leads to rapid plaque progression and instability through upregulation of matrix metalloproteinases (MMPs) and collagen degradation. Hemoglobin-derived hemin during IPH promotes plaque instability. We investigated whether hemin affects MMP overexpression in macrophages and explored the underlying mechanisms. Material and Methods In vivo, hemorrhagic plaque models were established in rabbits and ApoE−/− mice. Ferrostatin-1 was used to inhibit ferroptosis. Plaque size, collagen, and MMP2/9 levels were evaluated using immunohistochemistry, H&E, Sirius Red, and Masson staining. In vitro, mouse peritoneal macrophages were extracted. Western blot and ELISA were used to measure MMP2/9 levels. Bioinformatics analysis investigated the association between MMPs and ferroptosis pathway genes. Macrophage ferroptosis was assessed by evaluating cell viability, lipid reactive oxygen species, mitochondrial ultrastructure, iron content, and COX2 levels after pretreatment with cell death inhibitors. Hemin's impact on ferroptosis and MMP expression was studied using Ferrostatin-1 and SB202190. Results In the rabbit hemorrhagic plaques, hemin deposition and overexpression of MMP2/9 were observed, particularly in macrophage-enriched regions. In vitro, hemin induced ferroptosis and MMP2/9 expression in macrophages. Ferrostatin-1 and SB202190 inhibited hemin-induced MMP2/9 overexpression. Ferrostatin-1 inhibited p38 phosphorylation in macrophages. Ferostatin-1 inhibits macrophage ferroptosis, reduces MMP2/9 levels in plaques, and stabilizes the hemorrhagic plaques. Conclusion Our results suggested that hemin-induced macrophage ferroptosis promotes p38 pathway activation and MMP2/9 overexpression, which may play a crucial role in increasing hemorrhagic plaque vulnerability. These findings provide insights into the pathogenesis of hemorrhagic plaques and suggest that targeting macrophage ferroptosis may be a promising strategy for stabilizing vulnerable plaque.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-10-09T13:48:55+01:00
      DOI: 10.1055/a-2173-3602
      Issue No: Vol. eFirst
       
  • Effect of Previous INR Control during VKA Therapy on Subsequent DOAC
           Adherence and Persistence, in Patients Switched from VKA to DOAC

    • Free pre-print version: Loading...

      Authors: Elling; Tessa, Hak, Eelko, Bos, Jens H., Tichelaar, Vladimir Y. I. G., Veeger, Nic J. G. M., Meijer, Karina
      Pages: Abstract: Introduction Current guideline suggests a switch from vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) in patients with low time in therapeutic range (TTR 
      Citation: Thromb Haemost ; : -
      PubDate: 2023-10-09T13:47:02+01:00
      DOI: 10.1055/a-2168-9378
      Issue No: Vol. eFirst
       
  • Effect of Oral Anticoagulants in Atrial Fibrillation Patients with
           Polypharmacy: A Meta-analysis

    • Free pre-print version: Loading...

      Authors: Zheng; Yuxiang, Li, Siyuan, Liu, Xiao, Lip, Gregory Y. H., Guo, Linjuan, Zhu, Wengen
      Pages: Abstract: Background The aim of the present meta-analysis was to evaluate the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with polypharmacy. Methods and Results Randomized controlled trials or observational studies reporting the data of NOACs versus VKAs among AF patients with polypharmacy were included. The search was performed in the PubMed and Embase databases up to November 2022. A total of 12 studies involving 767,544 AF patients were included. For the primary outcomes, the use of NOACs compared with VKAs was significantly associated with a reduced risk of stroke or systemic embolism in AF patients with moderate polypharmacy (hazard ratio [HR]: 0.77 [95% confidence interval [CI]: 0.69–0.86]) and severe polypharmacy (HR: 0.76 [95% CI: 0.69–0.82]), but there was no significant difference in major bleeding (moderate polypharmacy: HR: 0.87 [95% CI: 0.74–1.01]; severe polypharmacy: HR: 0.91 [95% CI: 0.79–1.06]) between the two groups. In secondary outcomes, there were no differences in the rates of ischemic stroke, all-cause death, and gastrointestinal bleeding between the NOAC- and VKA- users, but NOAC users had a reduced risk of any bleeding compared with VKA- users. Compared with VKAs, the risk of intracranial hemorrhage was reduced in NOAC- users with moderate polypharmacy but not severe polypharmacy. Conclusion In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.
      Citation: Thromb Haemost ; : -
      PubDate: 2023-07-03T14:09:47+01:00
      DOI: 10.1055/s-0043-1770724
      Issue No: Vol. eFirst
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.201.97.0
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-
JournalTOCs
 
 
  Subjects -> MEDICAL SCIENCES (Total: 8186 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 153 of 153 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 3)
Acta Haematologica     Full-text available via subscription   (Followers: 18)
Acta Haematologica Polonica     Open Access  
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 46)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 14)
Archives of Hematology Case Reports and Reviews     Open Access  
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 25)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 3)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 285)
Blood Advances     Open Access   (Followers: 9)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 21)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 5)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 27)
Blood Pressure     Open Access   (Followers: 1)
Blood Pressure Monitoring     Hybrid Journal   (Followers: 2)
Blood Purification     Full-text available via subscription   (Followers: 5)
Blood Reviews     Hybrid Journal   (Followers: 20)
BMC Hematology     Open Access   (Followers: 6)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 23)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 15)
British Journal of Diabetes & Vascular Disease     Open Access   (Followers: 14)
British Journal of Haematology     Hybrid Journal   (Followers: 54)
British Journal of Primary Care Nursing - Cardiovascular Disease, Diabetes and Kidney Care     Full-text available via subscription   (Followers: 7)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 9)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 28)
Clinical Diabetes     Full-text available via subscription   (Followers: 30)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 14)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Clinical Lymphoma Myeloma and Leukemia     Hybrid Journal   (Followers: 6)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 1)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 14)
Current Diabetes Reviews     Hybrid Journal   (Followers: 13)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 14)
Cytotherapy     Full-text available via subscription   (Followers: 1)
Der Diabetologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 251)
Diabetes aktuell     Hybrid Journal   (Followers: 2)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 8)
Diabetes Care     Full-text available via subscription   (Followers: 281)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 10)
Diabetes Management     Full-text available via subscription   (Followers: 7)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 18)
Diabetes Spectrum     Full-text available via subscription   (Followers: 14)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 8)
Diabetes Therapy     Open Access   (Followers: 13)
Diabetic Foot & Ankle     Open Access   (Followers: 10)
Diabetic Medicine     Hybrid Journal   (Followers: 92)
Diabetologia     Hybrid Journal   (Followers: 105)
Diabetologia Kliniczna     Hybrid Journal  
Diabetologie und Stoffwechsel     Hybrid Journal  
Egyptian Journal of Haematology     Open Access  
Egyptian Journal of Hematology and Bone Marrow Transplantation     Open Access   (Followers: 10)
eJHaem     Open Access   (Followers: 1)
European Journal of Haematology     Hybrid Journal   (Followers: 12)
Experimental Hematology     Hybrid Journal   (Followers: 3)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Global Journal of Transfusion Medicine     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 35)
Haemophilia     Hybrid Journal   (Followers: 15)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematología     Open Access  
Hematology     Open Access   (Followers: 9)
Hematology Reports     Open Access   (Followers: 4)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hematology/Oncology and Stem Cell Therapy     Open Access   (Followers: 5)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 3)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access   (Followers: 1)
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 5)
International Journal of Diabetes Research     Open Access   (Followers: 6)
International Journal of Hematologic Oncology     Open Access   (Followers: 2)
International Journal of Hematology     Hybrid Journal   (Followers: 3)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Hematology-Oncology and Stem Cell Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 24)
Iraqi Journal of Hematology     Open Access  
JMIR Diabetes     Open Access  
Journal of Blood Disorders & Transfusion     Open Access   (Followers: 3)
Journal of Cell Science & Therapy     Open Access   (Followers: 1)
Journal of Applied Hematology     Open Access   (Followers: 2)
Journal of Blood Medicine     Open Access  
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 12)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 13)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 6)
Journal of Diabetes Investigation     Open Access   (Followers: 6)
Journal of Diabetes Mellitus     Open Access   (Followers: 4)
Journal of Diabetes Research     Open Access   (Followers: 9)
Journal of Diabetes Research     Open Access   (Followers: 4)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology     Open Access   (Followers: 2)
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Hypo & Hyperglycemia     Partially Free   (Followers: 1)
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 6)
Journal of Social Health and Diabetes     Open Access  
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 52)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 30)
Journal of Transfusion Medicine     Full-text available via subscription  
Kidney and Blood Pressure Research     Open Access   (Followers: 3)
Leukemia     Hybrid Journal   (Followers: 23)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 13)
Leukemia Research     Hybrid Journal   (Followers: 9)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Mediterranean Journal of Hematology and Infectious Diseases     Open Access  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 18)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 6)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Plasmatology     Open Access   (Followers: 1)
Platelets     Hybrid Journal   (Followers: 2)
Practical Diabetes     Hybrid Journal   (Followers: 4)
Primary Care Diabetes     Hybrid Journal   (Followers: 16)
Research & Reviews : Journal of Oncology and Hematology     Full-text available via subscription  
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 2)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 28)
Thalassemia Reports     Open Access   (Followers: 1)
The Lancet Haematology     Full-text available via subscription   (Followers: 42)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 110)
Thrombosis Research     Hybrid Journal   (Followers: 30)
Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie     Hybrid Journal  
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 11)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Similar Journals
HOME > Browse the 73 Subjects covered by JournalTOCs  
SubjectTotal Journals
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.201.97.0
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-